Tweet
Good evening,
Spravato is a new medication recently approved by the FDA for treatment-resistant depression. The active ingredient is esketamine.
Dr. Hale, what do you project the safety of this medicine to be when exclusively breastfeeding a full-term 3 month old baby with no medical concerns?
I would be concerned about continuous exposure to the infant when treating depression versus a one time use as an anesthetic. What concerns do you foresee, if any?
Thank you in advance.
MNicole
Spravato is a new medication recently approved by the FDA for treatment-resistant depression. The active ingredient is esketamine.
Dr. Hale, what do you project the safety of this medicine to be when exclusively breastfeeding a full-term 3 month old baby with no medical concerns?
I would be concerned about continuous exposure to the infant when treating depression versus a one time use as an anesthetic. What concerns do you foresee, if any?
Thank you in advance.
MNicole
Comment